Keywords: erbitux, cuts, mcrc, progression, risk, data, published

Erbitux cuts mCRC progression risk 32%

Article | 07 April 2009

Print This

Data published in the March 27 issue of the New England Journal of Medicine show the efficacy of German firm Merck ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in